Advertisement

Topics

Encouraging Response Observed with Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003

07:00 EST 10 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
First disclosure of anti-tumor activity from the bladder and cervical cancer cohorts showed objective response rates of 32% and 14%, respectively, and was 46% and 25% in patients who express PD-L1 ≥1% Increased prolif...

Other Sources for this Article

Bristol-Myers Squibb
Media:
Audrey Abernathy, 919-605-4521
audrey.abernathy@bms.com
or
Investors:
Tim Power, 609-252-7509
timothy.power@bms.com
or
Bill Szablewski, 609-252-5894
william.szablewski@bms.com

NEXT ARTICLE

More From BioPortfolio on "Encouraging Response Observed with Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bladder Cancer
Non-invasive bladder cancer is a cancer that is only in the inner lining of the bladder. Invasive bladder cancer is cancer that has spread into the deeper walls of the bladder. When the cancer has spread outside the bladder to other parts of the body, th...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...